takeda oncology originally millennium pharmaceuticals biopharmaceutical company based cambridge massachusetts fully owned subsidiary takeda pharmaceutical takeda oncologys research development commercialization activities focused two therapeutic areas oncology inflammation develop line new product candidates one first companies systematically search genes linked although none drugs marketing clinical trial one partial exception results particularly known bringing bortezomib marketed velcade clinical trials approval treatment patients multiple myeloma us fda growing clinical development pipeline product candidates may japanese company takeda pharmaceutical announced completion acquisition millennium per share deal worth billion takeda completed acquisition tender offer subsequent merger wholly owned subsidiary millennium takeda oncology company name simplified takeda oncology millennium founded mark j levin ceo cambridge massachusetts early years millennium focused building science business teams beginning millennium created strategic alliances pharmaceutical biotechnology companies alliances provided millennium close billion committed funding used develop enhance pipeline merger leukosite brought company first drug closetomarket campath alemtuzumab injection additional investigational drugs clinical trials merger cambridge discovery chemistry gave millennium strong presence united kingdom added organization scientists expertise chemistry strategic business decision campath later sold millennium partner drug ilex oncology turn acquired genzyme february merger cor largest mergers history biotech industry time addition creating strong pipeline novel therapeutics merger added cardiovascular research drug development companys key therapeutic areas oncology inflammation merger also brought integrilin eptifibatide injection intravenous antiplatelet drug patients severe cardiovascular diseases millennium fold millennium partnered scheringplough development marketing integrilin millennium licensed exclusive us commercialization development rights integrilin scheringplough may velcade launched treatment relapsed refractory multiple myeloma cancer blood time us food drug administration fda granted approval treatment multiple myeloma patients responded least two therapies disease velcade first fdaapproved proteasome inhibitor reached market record time represented first treatment decade approved patients multiple myeloma late december millennium successfully submitted supplemental new drug application snda fda velcade previously untreated multiple myeloma snda submitted fda indication included data phase iii study large wellcontrolled international clinical trial comparing velcadebased regimen traditional standard care priority review granted fda january june fda approved velcade combination patients previously untreated multiple myeloma means millennium market velcade patients prior therapies multiple myeloma firstline therapy may takeda pharmaceutical company limited purchased millennium billion millennium operating independent subsidiary serving global center excellence oncology new name millennium takeda oncology company global footprint includes oncology research marketing strategy oversight addition cambridge oncology resources include facilities san diego san francisco tsukuba osaka millennium global hub critical rapidly expanding therapeutic area summer decision made takeda drop millennium brand effectively renaming subsidiary takeda oncology however millennium pharmaceuticals inc still legal holding takeda name still used ongoing legal processes velcade first oncology drug marketed promoted millennium velcade granted fda approval little four half years initiation first clinical trial discover develop treatments company focuses key molecular pathways play crucial roles underlying disease processes identifying therapeutically significant differences may exist among people takeda oncology applies approach broadly throughout rd program develop novel treatments cancer also number important diseases velcade codeveloped millennium pharmaceuticals johnson johnson pharmaceutical research development takeda responsible commercialization velcade us janssencilag responsible commercialization europe rest world janssen pharmaceutical kk responsible commercialization japan limited period time takeda ortho biotech co promoting velcade us approved countries least patients treated velcade globally httpsenwikipediaorgwikitakedaoncology